Gaming and Leisure Properties Inc. Common Stock vs TG Therapeutics Inc — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.15B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: Gaming and Leisure Properties Inc. Common Stock is the larger of the two by market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| GLPI | TGTX | |
|---|---|---|
Market Cap | $11.15B | $8.32B |
Volume | 1,865,490 | 1,001,204 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $59.06 |
52-Week Low | $37.59 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $19.21B | $8.52B |
Dividend Yield | 8.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →